BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23234802)

  • 1. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis.
    Bilton D; Bellon G; Charlton B; Cooper P; De Boeck K; Flume PA; Fox HG; Gallagher CG; Geller DE; Haarman EG; Hebestreit HU; Kolbe J; Lapey A; Robinson P; Wu J; Zuckerman JB; Aitken ML;
    J Cyst Fibros; 2013 Jul; 12(4):367-76. PubMed ID: 23234802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
    Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
    Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.
    De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A;
    J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
    Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
    Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
    Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
    Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannitol dry powder for inhalation: in patients with cystic fibrosis.
    Burness CB; Keating GM
    Drugs; 2012 Jul; 72(10):1411-21. PubMed ID: 22755516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled mannitol improves lung function in cystic fibrosis.
    Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B
    Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
    Teper A; Jaques A; Charlton B
    J Cyst Fibros; 2011 Jan; 10(1):1-8. PubMed ID: 20888307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial.
    Minasian C; Wallis C; Metcalfe C; Bush A
    Thorax; 2010 Jan; 65(1):51-6. PubMed ID: 19996349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled mannitol for the treatment of cystic fibrosis.
    Hurt K; Bilton D
    Expert Rev Respir Med; 2012 Feb; 6(1):19-26. PubMed ID: 22283575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled mannitol and cystic fibrosis. Unnecessary bronchial irritation.
    Prescrire Int; 2014 Apr; 23(148):89-91. PubMed ID: 24860889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Effectiveness of Inhaled Mannitol (Bronchitol
    Warren E; Morgan K; Toward TJ; Schwenkglenks M; Leadbetter J
    Pharmacoeconomics; 2019 Mar; 37(3):435-446. PubMed ID: 30666534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled Dry Powder Mannitol Treatment in Pediatric Patients with Cystic Fibrosis: Evaluation of Clinical Data in a Real-World Setting.
    Duman I; Ünal G; Yilmaz AI; Güney AY; Durduran Y; Pekcan S
    Pediatr Allergy Immunol Pulmonol; 2022 Mar; 35(1):19-26. PubMed ID: 35285672
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.
    Daviskas E; Anderson SD; Jaques A; Charlton B
    Chest; 2010 Apr; 137(4):861-8. PubMed ID: 19880909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis.
    Minasian C; Wallis C; Metcalfe C; Bush A
    Pediatr Pulmonol; 2008 Nov; 43(11):1078-1084. PubMed ID: 18972410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.
    Flume PA; Amelina E; Daines CL; Charlton B; Leadbetter J; Guasconi A; Aitken ML
    J Cyst Fibros; 2021 Nov; 20(6):1003-1009. PubMed ID: 33715994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.
    Ademhan Tural D; Yalçın E; Emiralioglu N; Ozsezen B; Sunman B; Nayir Buyuksahin H; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Pulmonol; 2022 Jan; 57(1):142-151. PubMed ID: 34687284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation.
    Middleton A; Robinson PD; McKay K; Jaffe A; Selvadurai H
    Eur Respir J; 2015 Feb; 45(2):541-4. PubMed ID: 25359334
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
    Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
    Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline.
    Brannan JD; Anderson SD; Perry CP; Freed-Martens R; Lassig AR; Charlton B;
    Respir Res; 2005 Dec; 6(1):144. PubMed ID: 16336673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.